KR20150022177A - Composition comprising solvent fractionated extracts of Zingiber officinale, which are useful for the prevention, improvement and treatment of functional gastrointestinal and motility disorders - Google Patents
Composition comprising solvent fractionated extracts of Zingiber officinale, which are useful for the prevention, improvement and treatment of functional gastrointestinal and motility disorders Download PDFInfo
- Publication number
- KR20150022177A KR20150022177A KR20130099628A KR20130099628A KR20150022177A KR 20150022177 A KR20150022177 A KR 20150022177A KR 20130099628 A KR20130099628 A KR 20130099628A KR 20130099628 A KR20130099628 A KR 20130099628A KR 20150022177 A KR20150022177 A KR 20150022177A
- Authority
- KR
- South Korea
- Prior art keywords
- ginger
- fraction
- gastrointestinal
- gastrointestinal motility
- disorder
- Prior art date
Links
- 235000006886 Zingiber officinale Nutrition 0.000 title claims abstract description 83
- 235000008397 ginger Nutrition 0.000 title claims abstract description 83
- 230000002265 prevention Effects 0.000 title claims description 6
- 244000273928 Zingiber officinale Species 0.000 title abstract description 6
- 239000001841 zingiber officinale Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title description 22
- 239000000284 extract Substances 0.000 title description 19
- 230000002496 gastric effect Effects 0.000 title description 12
- 239000002904 solvent Substances 0.000 title description 5
- 230000004899 motility Effects 0.000 title description 4
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 30
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 241000234314 Zingiber Species 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- 230000036541 health Effects 0.000 claims description 17
- 235000013376 functional food Nutrition 0.000 claims description 15
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims description 14
- 239000012223 aqueous fraction Substances 0.000 claims description 13
- 206010010774 Constipation Diseases 0.000 claims description 12
- 239000002037 dichloromethane fraction Substances 0.000 claims description 10
- 206010047700 Vomiting Diseases 0.000 claims description 8
- 201000006549 dyspepsia Diseases 0.000 claims description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 8
- 230000008673 vomiting Effects 0.000 claims description 8
- 239000000401 methanolic extract Substances 0.000 claims description 7
- 206010054048 Postoperative ileus Diseases 0.000 claims description 6
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 6
- 206010021518 Impaired gastric emptying Diseases 0.000 claims description 5
- 208000012902 Nervous system disease Diseases 0.000 claims description 5
- 208000025966 Neurological disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 230000003412 degenerative effect Effects 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 5
- 208000001288 gastroparesis Diseases 0.000 claims description 5
- 208000003243 intestinal obstruction Diseases 0.000 claims description 5
- 239000000014 opioid analgesic Substances 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims description 4
- 229940005483 opioid analgesics Drugs 0.000 claims description 4
- 230000002980 postoperative effect Effects 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 230000007661 gastrointestinal function Effects 0.000 claims 1
- 230000005176 gastrointestinal motility Effects 0.000 abstract description 19
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 238000009825 accumulation Methods 0.000 abstract description 2
- 230000035508 accumulation Effects 0.000 abstract description 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000008602 contraction Effects 0.000 description 33
- 230000000694 effects Effects 0.000 description 25
- 210000002784 stomach Anatomy 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 23
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 20
- 229960004373 acetylcholine Drugs 0.000 description 20
- 235000013305 food Nutrition 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 241000700199 Cavia porcellus Species 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 8
- 230000002269 spontaneous effect Effects 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000002747 voluntary effect Effects 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 229940002508 ginger extract Drugs 0.000 description 5
- 235000020708 ginger extract Nutrition 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 4
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000004203 pyloric antrum Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000019430 Motor disease Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- -1 0.04%) Chemical compound 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 229940124575 antispasmodic agent Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 235000013550 pizza Nutrition 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000057413 Motilin receptors Human genes 0.000 description 1
- 108700040483 Motilin receptors Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- 230000001330 gastroprokinetic effect Effects 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940027779 persimmon extract Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036972 phasic contraction Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000387 serotonin 5-HT4 receptor agonist Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036977 tonic contraction Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 1
- 229930001895 zingiberene Natural products 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
Description
본 발명은 생강의 용매분획을 유효성분으로 포함하는 기능성 위장장애 및 위장관 운동장애의 예방 및 치료용 약학적 조성물에 관한 것이다. The present invention relates to a pharmaceutical composition for preventing and treating a functional gastrointestinal disorder and gastrointestinal motility disorder comprising an active ingredient of a solvent fraction of ginger.
기능성 위장 장애(functional gastrointestinal disorders)는 구조적 또는 생화학적으로 설명할 수 없는 위장관 증상이 만성 또는 재발성으로 나타나는 경우로 정의된다. 기능성 위장 장애는 동서양을 막론하고 높은 유병률을 보이고 있으며, 특히 소화기 계통의 환자들 중에서는 가장 많은 질환으로 알려져 있다.Functional gastrointestinal disorders are defined as chronic or recurrent gastrointestinal symptoms that can not be explained structurally or biochemically. Functional gastrointestinal disorders have a high prevalence both east and west, especially among the digestive system patients.
과거에는 소화불량(indigestion), 상복부 팽만감(abdominal fullness), 상복부 통증(abdominal pain) 등 주로 상부 위장관 증상을 보이는 경우에 기능성 위장 장애라고 하였으나, 최근에는 이러한 경우를 기능성 소화 불량증(functional dyspepsia)이라고 부른다. 하부 위장관 증상에는 변비(constipation), 설사(diarrhea), 복부팽만감, 하복부동통, 우상복부불쾌감(abdominal discomfort) 등이 있다. 기능성 위장 장애는 상부 위장관 증상과 하부 위장관 증상에 대한 포괄적인 의미로 사용한다. 따라서 기능성 위장장애에는 식도, 위, 십이지장, 소장, 대장, 담관 등의 기능성 장애가 모두 포함된다. 이중 상부 위장관 증상을 보이는 기능성 소화 불량증과 하부 위장관 증상을 주로 나타내는 과민성 장 증후군(irritable bowel syndrome)이 기능성 위장 장애의 대표적인 질환이다. In the past, functional gastrointestinal disorder was referred to as a functional gastrointestinal disorder in the cases of upper gastrointestinal symptoms such as indigestion, abdominal fullness, and abdominal pain. In recent years, such a condition is referred to as functional dyspepsia . Symptoms of the lower gastrointestinal tract include constipation, diarrhea, abdominal bloating, abdominal pain, and abdominal discomfort. Functional gastrointestinal disorders are used in a comprehensive sense of upper gastrointestinal symptoms and lower gastrointestinal symptoms. Thus, functional gastrointestinal disorders include functional disorders such as esophagus, stomach, duodenum, small intestine, large intestine, and bile ducts. Functional dyspepsia with upper gastrointestinal symptoms and irritable bowel syndrome (lower gastrointestinal symptoms) are the most common functional gastrointestinal disorders.
기능성 위장 장애는 위장관 운동성(gastrointestinal motility)이나 감각기능이 개별적으로 이상이 있는 경우와 두 가지가 모두 이상이 있는 경우가 있다. 위장관 운동성이 잘 조율되는 것은 섭취한 음식물의 효율적인 소화와 영양분 흡수를 위해서 필수적이며, 소화가 되지 않는 잔여물을 체외로 배출하기 위해서도 중요하다. 따라서, 위장관 운동성에 이상이 생기면 설사, 변비 및 복통(abdominal pain) 등의 증상을 일으킬 수 있으며, 운동성의 이상이 심한 경우에는 영양소의 흡수까지 장애를 일으킬 수 있다. Functional gastrointestinal disorders include gastrointestinal motility, sensory disturbances, or both. Good coordination of gastrointestinal motility is essential for efficient digestion and absorption of nutrients in the food consumed, and is also important for excretion of non-digestible residues. Therefore, if gastrointestinal motility is abnormal, it can cause diarrhea, constipation and abdominal pain. In case of abnormality of mobility, it can cause up to absorption of nutrients.
위장관의 운동성은 위장관 평활근(gastrointestinal smooth muscle)의 수축조절에 기반을 두고 있다. 위장관 평활근의 수축이 심해지면 연축(spasm)이 발생하며, 이완이 너무 심해지면 마비(paralysis)가 나타난다. 여러 가지 외인성 물질과 내인성 물질이 위장관 평활근의 수축력을 조절할 수 있다. 위장관 운동성은 선행질환이나 치료용 약물에 의해서도 영향을 받을 수 있으므로, 기능성 위장 장애 및 운동장애(functional gastrointestinal and motility disorders)라는 용어로 위장관 운동성 변화가 유발하는 여러가지 증상군을 설명하고 있다.The motility of the gastrointestinal tract is based on the contraction control of the gastrointestinal smooth muscle. When the contraction of the smooth muscle of the gastrointestinal tract becomes severe, spasm occurs. When the relaxation becomes too severe, paralysis occurs. Several exogenous and endogenous substances can modulate the contractile force of the smooth muscle of the gastrointestinal tract. Because gastrointestinal motility may also be affected by prior illnesses and therapeutic drugs, the term "functional gastrointestinal and motility disorders" describes various symptom groups that cause gastrointestinal motility changes.
기능성 위장 장애 및 운동장애에 대한 치료제로서 관심을 끌고 있는 표적은 다음과 같다: 세로토닌 수용체 아형3(5-HT3) 길항제, 세로토닌 수용체 아형4(5-HT4) 작동제, 부신피질자극호르몬 유리인자(Corticotropin Releasing Factor, CRF) 길항제, 그렐린(ghrelin), 뉴로키닌(neurokinin), 산화질소(nitric oxide) 및 기타 기체 신경전달물질, 아편양 수용체 뮤-아형 조절(mu-opioid receptor modulation), 칸나비노이드(cannabinoids), 비만세포 안정제(mast cell stabilizer).Targets that are of interest as therapeutic agents for functional gastrointestinal and motor disorders are: serotonin receptor subtype 3 (5-HT3) antagonist, serotonin receptor subtype 4 (5-HT4) agonist, adrenocorticotropic hormone Corticotropin Releasing Factor (CRF) antagonists, ghrelin, neurokinin, nitric oxide and other gaseous neurotransmitters, mu-opioid receptor modulation, Cannabinoids, mast cell stabilizers.
이와 같은 여러 가지 표적이 고려되고 있는 것은 아직까지도 기능성 위장 장애 및 운동장애의 병태생리가 완전히 규명되지 않았음을 반영하는 것이다. 여러 가지 증상을 해소하기 위하여 현재 사용되고 있는 약물은 대개는 위장관 운동성을 촉진하거나 감소시키는 약물들이다. 약물군별로 살펴보자면, 도파민 길항제(dopamine antagonist)나 세로토닌 수용체 아형4의 작동제(5-HT4 agonist)는 위배출을 자극하고 위장관 운동성을 증가시키는 위장운동촉진제(gastroprokinetic drug)로 이용할 수 있고, 항콜린성 약물(anticholinergics)나 칼슘통로 봉쇄제(calcium channel blocker)는 항연축제(antispasmodics)로 이용할 수 있다. 에리쓰로마이신(erythromycin)은 모틸린(motilin) 수용체에 대한 작용을 통하여 위장운동 촉진 작용을 약하게 나타낸다.These multiple targets are still considered to reflect the fact that the pathophysiology of functional gastrointestinal and motor disorders has not yet been fully characterized. Drugs currently used to relieve a variety of symptoms are drugs that promote or reduce gastrointestinal motility. The dopamine antagonist or the 5-HT4 agonist of the
위에서 제시된 약물들은 증상개선을 위하여 상당히 장기간 이용할 필요가 있어 약물의 선택에 있어서는 표적 증상 및 약물효과 뿐 아니라 부작용이 같이 고려되어야 한다. 도파민 길항제의 대표적인 부작용으로는 추체외로징후(extrapyramidal symptom)와 고프로락틴혈증(hyperprolactinemia) 등이 있다. 세로토닌 수용체 아형4 작용제로 개발된 시사프라이드(Cisapride)는 심전도에서 QT간격을 연장시키는 기전으로 부정맥 및 심인성 급사를 일으킬 수 있다고 하여 시장에서 철회되었다. The above-mentioned drugs need to be used for a long period of time in order to improve the symptoms. In selecting the drug, the side effects as well as the target symptom and the drug effect should be taken into consideration. Typical side effects of dopamine antagonists include extrapyramidal symptoms and hyperprolactinemia. Cisapride, a serotonin receptor subtype, has been withdrawn from the market because it can cause arrhythmia and cardiogenic death as a mechanism to prolong QT interval in ECG.
따라서, 종래의 위장관 운동성 조절약물들이 가지고 있는 문제점을 고려할 때, 부작용이 적고 치료 효능은 우수한 천연물 유래의 안전한 치료제의 개발이 시급한 실정이다. 이러한 약물은 기능성 위장 장애 및 운동장애로 인한 여러가지 증상이 발생하는 것을 안전하게 예방하거나 치료하는데 큰 도움을 줄 것이다.Therefore, when considering the problems of conventional gastrointestinal motility modulating drugs, it is urgently required to develop a safe therapeutic agent derived from natural materials with less side effects and excellent therapeutic efficacy. These medications will be of great help in safely preventing or treating the development of various symptoms due to functional gastrointestinal and motor disorders.
본 발명의 목적은 생체에 부작용이 없으면서 다양한 약리 효과를 갖는 생강 수용성 분획물 또는 비극성 분획물을 유효성분으로 함유하는 기능성 위장장애 및 위장관 운동장애의 예방 및 치료용 약학적 조성물을 제공하는 것이다.It is an object of the present invention to provide a pharmaceutical composition for preventing and treating a functional gastrointestinal disorder and gastrointestinal motility disorder containing, as an active ingredient, a ginger-soluble fraction or a non-polar fraction having various pharmacological effects without adverse effects on a living body.
또한, 본 발명의 목적은 생강 수용성 분획물 또는 생강 비극성 분획물을 유효성분으로 포함하는 기능성 위장장애 및 위장관 운동장애의 예방용 건강기능식품을 제공하는 것이다.It is another object of the present invention to provide a health functional food for preventing functional gastrointestinal disorder and gastrointestinal motility disorder comprising ginger-soluble fraction or ginger nonpolar fraction as an active ingredient.
상기와 같은 목적을 달성하기 위하여, 본 발명은 생강의 수용성 분획물 또는 비극성 분획물을 유효성분으로 포함하는 기능성 위장장애 및 위장관 운동장애의 예방 및 치료용 약학적 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing and treating a functional gastrointestinal disorder and gastrointestinal motility disorder comprising an aqueous fraction or a non-polar fraction of ginger as an active ingredient.
본 발명의 일실시예에 있어서, 상기 생강은 생강의 가지, 잎, 뿌리 및 생강 전체로 이루어진 군에서 선택되는 생강 부위를 사용할 수 있다. In one embodiment of the present invention, the ginger may be selected from the group consisting of branches, leaves, roots and whole ginger of ginger.
본 발명의 일실시예에 있어서, 상기 수용성 분획물은 물 분획물이며, 상기 비극성 분획물은 디클로로메탄 분획일 수 있다. In one embodiment of the present invention, the water soluble fraction is a water fraction, and the nonpolar fraction may be a dichloromethane fraction.
본 발명의 일실시예에 있어서, 상기 물 분획물은 생강의 메탄올 추출물에 물을 첨가하여 현탁한 후 물 분획물을 수득한 것이며, 상기 디클로로메탄 분획물은 생강의 메탄올 추출물에 디클로로메탄을 첨가하여 수득한 것일 수 있다. In one embodiment of the present invention, the water fraction is obtained by adding water to a methanol extract of ginger to obtain a water fraction, and the dichloromethane fraction is obtained by adding dichloromethane to a methanol extract of ginger .
본 발명의 일실시예에 있어서, 상기 기능성 위장장애 및 위장관 운동장애는 위식도 역류성 질환(gastroesophageal reflux disease), 위 마비(gastroparesis), 기능성 소화불량(functional dyspepsia), 과민성 대장증후군(irritable bowel syndrome), 대장 무력증(colonic inertia), 구토(vomiting), 당뇨병성 위장관 운동장애(diabetic gastrointestinal motility disorder), 화학요법 또는 약물(예, 아편양 진통제)로 인한 위장 운동장애, 소화관 운동장애로 인한 장폐색, 수술 후 장폐색증(postoperative ileus)을 포함하는 수술 후 위장관 기능 장애, 파킨슨병과 같은 퇴행성 신경질환과 관련한 위장관 운동장애, 변비(constipation)등으로 이루어진 군으로부터 선택된 1종 이상일 수 있다. In one embodiment of the present invention, the functional gastrointestinal disorder and gastrointestinal motility disorder is selected from the group consisting of gastroesophageal reflux disease, gastroparesis, functional dyspepsia, irritable bowel syndrome, Gastrointestinal motility disorders due to colonic inertia, vomiting, diabetic gastrointestinal motility disorder, chemotherapy or drugs (eg, opioid analgesics), intestinal obstruction due to gastrointestinal motility disorders, surgery Post-operative gastrointestinal dysfunction including postoperative ileus, gastrointestinal motility disorders associated with degenerative neurological diseases such as Parkinson's disease, constipation, and the like.
또한, 본 발명은 생강의 물 분획물 또는 생강의 디클로로메탄 분획물을 유효성분으로 포함하는 위장관 운동장애의 예방 및 개선용 건강기능식품을 제공한다.The present invention also provides a health functional food for preventing or ameliorating gastrointestinal motility disorder comprising ginger water fraction or dichloromethane fraction of ginger as an active ingredient.
본 발명의 일실시예에 있어서, 상기 기능성 위장장애 및 위장관 운동장애는 위식도 역류성 질환(gastroesophageal reflux disease), 위 마비(gastroparesis), 기능성 소화불량(functional dyspepsia), 과민성 대장증후군(irritable bowel syndrome), 대장 무력증(colonic inertia), 구토(vomiting), 당뇨병성 위장관 운동장애(diabetic gastrointestinal motility disorder), 화학요법 또는 약물(예, 아편양 진통제)로 인한 위장 운동장애, 소화관 운동장애로 인한 장폐색, 수술 후 장폐색증(postoperative ileus)을 포함하는 수술 후 위장관 기능 장애, 파킨슨병과 같은 퇴행성 신경질환과 관련한 위장관 운동장애, 변비(constipation)등으로 이루어진 군으로부터 선택된 1종 이상일 수 있다.In one embodiment of the present invention, the functional gastrointestinal disorder and gastrointestinal motility disorder is selected from the group consisting of gastroesophageal reflux disease, gastroparesis, functional dyspepsia, irritable bowel syndrome, Gastrointestinal motility disorders due to colonic inertia, vomiting, diabetic gastrointestinal motility disorder, chemotherapy or drugs (eg, opioid analgesics), intestinal obstruction due to gastrointestinal motility disorders, surgery Post-operative gastrointestinal dysfunction including postoperative ileus, gastrointestinal motility disorders associated with degenerative neurological diseases such as Parkinson's disease, constipation, and the like.
본 발명에 따른 생강의 수용성 분획물은 위장관 운동을 증진시키는 효과가 우수하고, 비극성 분획물은 위장관 운동성을 감소시키는 효과가 우수하여 기능성 위장장애 및 위장관 운동장애와 관련된 증상의 예방 및 치료에 유용하게 사용할 수 있다.The water-soluble fraction of ginger according to the present invention has an excellent effect of promoting gastrointestinal motility, and the non-polar fraction has an excellent effect of reducing gastrointestinal motility, so that it can be effectively used for prevention and treatment of symptoms related to functional gastrointestinal disorders and gastrointestinal motility disorders have.
또한, 약물의 독성 및 이상반응, 체내 축적에 대한 걱정이 없이 장기간 복용할 수 있다.In addition, it can be taken for a long time without worrying about the toxicity and adverse reaction of the drug and accumulation in the body.
도 1은 생강의 용매 분획물(디클로로메탄 분획물, 수용성 분획물) 과정을 나타낸 모식도이다.
도 2는 기니피그 위조직 윤상근(circular muscle)의 자발적 수축에 대한 생강 수용성 분획물의 효과를 나타낸 결과이다.
도 3은 기니피그 위조직 윤상근의 자발적 수축에 대한 생강 수용성 분획물의 효과를 농도별로 측정한 결과이다.
도 4는 아세틸콜린에 의한 위조직 윤상근의 수축반응을 나타낸 모식도이다.
도 5는 위조직 윤상근에서의 아세틸콜린 및 생강 수용성 분획에 의한 수축반응 유발효과를 아세틸콜린 단독처리에 의한 수축반응과 비교한 결과이다.
도 6은 위조직의 자발적 수축에 대한 생강 디클로로메탄 분획물의 효과를 정량적으로 나타낸 결과이다.BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a schematic diagram showing the process of the ginger's solvent fraction (dichloromethane fraction, water-soluble fraction).
FIG. 2 shows the effect of ginger-soluble fraction on spontaneous contraction of the circular muscle of the guinea pig stomach.
FIG. 3 shows the results of measurement of the effect of the ginger-soluble fraction on the spontaneous contraction of the guinea pig gastric muscle.
Fig. 4 is a schematic diagram showing a shrinkage reaction of the stomach cortical muscle by acetylcholine. Fig.
FIG. 5 shows the results of shrinkage-induced effects of acetylcholine and ginger-soluble fractions in stomach circumference of the stomach compared with shrinkage responses of acetylcholine alone.
Figure 6 quantitatively shows the effect of the ginger dichloromethane fraction on spontaneous contraction of the stomach tissue.
본 발명은 생강의 비극성 분획물 및 수용성 분획물을 유효성분으로 포함하는 기능성 위장장애 및 위장관 운동장애의 예방 및 치료용 조성물을 제공함에 그 특징이 있다.The present invention is characterized by providing a composition for preventing and treating functional gastrointestinal disorder and gastrointestinal motility disorder comprising the non-polar fraction and the water-soluble fraction of ginger as an active ingredient.
“기능성 위장장애 및 위장관 운동장애”는 위식도 역류성 질환(gastroesophageal reflux disease), 위 마비(gastroparesis), 기능성 소화불량(functional dyspepsia), 과민성 대장증후군(irritable bowel syndrome), 대장 무력증(colonic inertia), 구토(vomiting), 당뇨병성 위장관 운동장애(diabetic gastrointestinal motility disorder), 화학요법 또는 약물(예, 아편양 진통제)로 인한 위장 운동장애, 소화관 운동장애로 인한 장폐색, 수술 후 장폐색증(postoperative ileus)을 포함하는 수술 후 위장관 기능 장애, 파킨슨병과 같은 퇴행성 신경질환과 관련한 위장관 운동장애, 변비(constipation)등과 같이 정상적인 위장관 운동이 항진, 협동장애(dyssyntergia), 저해, 손상 되어 있는 병적 상태를 말한다."Functional gastrointestinal disorders and gastrointestinal motility disorders" include gastroesophageal reflux disease, gastroparesis, functional dyspepsia, irritable bowel syndrome, colonic inertia, Including gastrointestinal motility disorders due to vomiting, diabetic gastrointestinal motility disorder, chemotherapy or drugs (eg, opioid analgesics), intestinal obstruction due to digestive tract movement disorders, postoperative ileus Refers to a condition in which normal gastrointestinal motility is hyperactivity, dyssyntergia, inhibition, or damage such as post-operative gastrointestinal dysfunction, gastrointestinal motility disorders associated with degenerative neurological diseases such as Parkinson's disease, constipation, and the like.
“생강”은 생강과에 속하는 아열대 및 열대성 다년생 식물로서, 우리나라 뿐만 아니라 세계적으로 널리 이용되고 있는 향신료의 하나이며, 식품의 관능성을 향상시키기 위해 첨가하는 조미성분의 하나로 사용되고 있다. 또한, 생강은 인체에 유익한 여러 가지 성분이 함유되어 있어 차(tea)나 약재로 널리 사용되어 왔다."Ginger" is a subtropical and tropical perennial plant belonging to the ginger family. It is one of the spices widely used not only in Korea but also in the world. It is used as one of the seasoning ingredients added to improve the sensuality of the food. In addition, ginger has various ingredients beneficial to the human body and has been widely used as tea or medicine.
한방에서는 생강의 뿌리줄기 말린 것을 건강(乾薑)이라는 약재로 사용하고 있는데, 구역 및 구토의 예방 및 치료에 효과가 있고, 혈액 순환을 촉진하며, 항염증과 진통효과를 지니고 있다. 생강의 75% 정도는 수분이고, 전체 고형분의 40 ~ 60%는 전분이 차지하고 있다. 정유성분으로는 진지베롤(zingiberol), 진지베렌(zingiberene) 등이 함유되어 있으며, 특이 성분으로 6-진저롤(6-gingerol, 0.1∼ 0.3%), 진저론(zingerone), 6-쇼가올(6-shogaol, 0.04%), 감마-아미노부티르산(gamma-aminobutyric acid) 등이 함유되어 있다고 알려져 있다.In one room, dried root of ginger is used as a medicinal product of health (dry), which is effective in prevention and treatment of area and vomiting, promotes blood circulation, has anti-inflammatory and analgesic effect. About 75% of ginger is water, and starch accounts for 40 ~ 60% of total solids. The essential oils contain zingiberol and zingiberene. Specific ingredients include 6-gingerol (0.1-0.3%), zingerone, 6-showol 6-shogaol, 0.04%), gamma-aminobutyric acid, and the like.
생강을 위장관 기능을 조절하기 위하여 사용한 기존의 노력은 구역 및 구토를 예방 및 치료하는데 집중되어 있다. 일부 연구에서는 위장관 운동성 조절을 위해 생강 추출물이나 분쇄된 건강(이하, 생강가루)을 사용하였다. 이러한 연구에서사용한 생강의 제형은 생강의 열수 추출물, 에탄올 추출물, 아세톤 추출물, 생강가루였는데, 생강의 제형에 따라 위장관 운동성의 증진 및 억제에 대한 효과가 일치하지 않았다. 이러한 불일치는 생강에 위장관의 운동성을 증진시키거나 억제시킬 수 있는 서로 다른 물질들이 존재함을 시사하였기에, 본 발명에서는 생강의 전체 추출물을 극성에 따라 두 분획으로 나눔으로써 위장관 운동성에 대하여 서로 상반된 방향으로 효과를 나타내는 물질군을 간단히 분리할 수 있음을 규명하였다. Conventional efforts to control gingival function of ginger have focused on preventing and treating areas and vomiting. In some studies, ginger extract or crushed health (hereinafter referred to as ginger powder) was used to control gastrointestinal motility. The ginger formulation used in this study was ginger hot water extract, ethanol extract, acetone extract, and ginger powder. The effect of ginger formulation on the enhancement and inhibition of gastrointestinal motility was not consistent. These inconsistencies suggest that there are different substances that can enhance or inhibit the motility of the gastrointestinal tract in the ginger. Therefore, in the present invention, by dividing the whole extract of ginger into two fractions according to the polarity, It was found that the effect group can be easily separated.
본 발명은 앞서 기술한 바와 같이 생강 추출물을 기능성 위장장애 및 위장관 운동장애의 예방 및 치료용 약학적 조성물로 사용하기 위해서는 생강 추출물을 수용성 분획물과 비극성 분획물로 나눔으로써 생강의 위장관 운동성 증진 및 억제 효과를 분리하여야 한다는 점을 규명하였다는 특징이 있다. In order to use the ginger extract as a pharmaceutical composition for the prevention and treatment of functional gastrointestinal disorder and gastrointestinal motility disorder as described above, the ginger extract is divided into the water-soluble fraction and the non-polar fraction, thereby improving the gastrointestinal motility and inhibiting effect of ginger It is necessary to separate them.
보다 구체적으로 본 발명의 일실시예에 의하면, 위조직 윤상근(circular muscle)에 생강 수용성 분획물을 처리한 뒤 기니피그 위조직 윤상근의 자발적 수축 정도를 살펴본 결과, 생강 수용성 분획물의 농도가 증가함에 따란 기니피그 위조직 윤상근의 자발적 수축의 크기가 증가함을 알 수 있었다(도 2참조).More specifically, according to one embodiment of the present invention, the spontaneous shrinking degree of the guinea pig gastric muscle after treating the gingival water-soluble fraction in the stomach tissue of the stomach was found to be higher than that of the guinea pig And the size of the voluntary contraction of the tissue was increased (see FIG. 2).
또 다른 일실시예에 의하면, 아세틸콜린에 의한 사람 위조직 윤상근의 수축반응을 측정한 결과, 아세틸콜린 단독 처리에 의해 유발된 peak 수축, 위상성 수축, 장력성 수축의 크기를 100%로 기준을 정했을 때, 생강 수용성 분획 및 아세틸콜린에 의해서는 peak수축이 223± 34%, 장력성 수축이 97± 66%, 위상성 수축이 216± 28%으로 변하였다. 장력성 수축은 아세틸콜린 단독 또는 생강 수용성 분획 병용투여에 의하여 유의한 변화가 없었으나, 생강의 수용성 분획은 아세틸콜린 단독에 의해 유발된 peak 수축 및 위상성 수축의 크기를 각각 2배 정도 증가시킴을 알 수 있었다(도 5 참조).According to another embodiment of the present invention, the shrinkage of the human stomach tissue by acetylcholine was measured. As a result, the size of peak shrinkage, phase shrinkage and tensile shrinkage caused by acetylcholine alone treatment was 100% When the ginger water soluble fraction and acetylcholine were used, the peak shrinkage was 223 ± 34%, the tension shrinkage was 97 ± 66%, and the phase shrinkage was 216 ± 28%. Tension contraction was not significantly altered by the administration of acetylcholine alone or in combination with the ginger aqueous fraction. However, the water soluble fraction of ginger increased peak shrinkage and phase contraction induced by acetylcholine alone by a factor of 2 (See Fig. 5).
또 다른 일실시예에 있어서, 위조직의 자발적 수축에 대한 생강 비극성 분획의 효과를 측정한 결과, 생강 비극성 분획물 투여전의 장력을 대조군으로 할 경우, 생강 비극성 분획물 투여 후에는 장력이 각각 25± 15%, 2± 2%, 0%로 감소함을 알 수 있었다(도 6참조).In another embodiment, the effect of ginger nonpolar fraction on spontaneous contraction of the stomach tissue was measured. As a result, when the gingival nonpolar fraction was used as a control, the tension was 25 ± 15% , 2 ± 2% and 0%, respectively (see FIG. 6).
위의 결과를 종합하자면, 생강의 수용성 분획물은 위 조직의 수축력을 증가시키고, 비극성 분획물은 위 조직의 수축력을 감소시키는 효과가 있다. 위 조직의 수축력이 증가하면 위배출이 촉진되고 및 위장관 운동성이 증가할 수 있으므로, 생강의 수용성 분획물은 위장운동촉진제(prokinetics)의 역할을 할 수 있음을 알 수 있었고, 반면, 위 조직의 수축력 감소효과를 이용하면 위장관 평활근의 연축(spasm)을 억제할 수 있으므로, 생강의 비극성 분획물은 항연축제(antispasmodics)의 효과를 나타내어 설사증상을 완화 시키는데 이용할 수 있음을 알 수 있었다.Taken together, the water soluble fraction of ginger increases the contractile force of the stomach tissue and the nonpolar fraction has the effect of reducing the contractile force of stomach tissue. As the contraction force of the stomach increases, gastric emptying is accelerated and gastrointestinal motility increases, so that the aqueous fraction of ginger can act as a prokinetics promoter, Effect can inhibit spasm of the smooth muscle of the gastrointestinal tract. Therefore, the non-polar fraction of ginger can be used to alleviate diarrhea symptoms by showing the effect of antispasmodics.
또한, 본 발명에 따른 생강 추출물은 당 업계에 공지된 추출 및 분리하는 방법을 사용하여 천연물로부터 추출 및 분리하여 수득한 것을 사용할 수 있으며, 본 발명에서 정의된 ‘추출물’은 적절한 용매를 이용하여 생강으로부터 추출한 것이며, 본 발명의 추출물은 디클로로메탄, 헥산 또는 사염화탄소 등의 비극성용매 추출물 또는 생강의 열수추출물 또는 극성용매 가용 추출물을 의미하며, 생강으로부터 비극성 분획물 또는 수용성 분획물을 추출하기 위한 적절한 용매로는 당업계에서 허용되는 비극성 용매라면 어느 것을 사용해도 무방하다. In addition, the ginger extract according to the present invention can be obtained by extracting and isolating from a natural product using extraction and separation methods known in the art, and the 'extract' defined in the present invention can be prepared by extracting ginger And the extract of the present invention means a non-polar solvent extract such as dichloromethane, hexane or carbon tetrachloride or a hot water extract or a polar solvent soluble extract of ginger. As a suitable solvent for extracting non-polar fractions or water-soluble fractions from ginger, Any non-polar solvent acceptable in the industry may be used.
추출 방법으로는 열수추출법, 냉침추출법, 환류냉각추출법, 용매추출법, 수증기증류법, 초음파추출법, 용출법, 압착법 등의 방법 중 어느 하나를 선택하여 사용할 수 있다. As the extraction method, any one of the methods such as hot water extraction method, cold extraction method, reflux cooling extraction method, solvent extraction method, steam distillation method, ultrasonic extraction method, elution method and compression method can be selected and used.
예컨대, 열수추출법은 추출하고자 하는 유효성분을 물과 열을 가하여 추출하는 방법으로서, 보통 식물로부터 추출물을 수득하는데 많이 사용되고 있는 방법이며, 또한 초음파 추출법은 초음파를 이용하여 천연물의 변형 없이 추출하는 방법으로서 열수추출법보다 원재료의 절감이 있는 특징이 있다. For example, the hydrothermal extraction method is a method of extracting an effective ingredient to be extracted by applying water and heat, and is usually used for obtaining an extract from a plant. The ultrasonic extraction method is a method for extracting natural products without deformation using ultrasonic waves It is characterized by the reduction of raw material rather than hot water extraction method.
냉침추출법은 열을 가하지 않고 유효성분을 추출하는 방법으로서 열을 사용하지 않음으로 유효성분의 손실 및 활성파괴 등을 감소시킬 수 있는 특징이 있어, 특히 열에 민감한 활성성분을 함유하는 추출물인 경우, 냉침 추출법을 사용하는 것이 바람직하다.In the method of extracting the active ingredient without applying heat, the method of extracting the active ingredient from the cold extract method is characterized in that loss of the active ingredient and active breakage can be reduced by not using heat. Especially, in the case of the extract containing the heat- It is preferable to use an extraction method.
환류추출법은 액체를 끓여서 수증기를 만들고 이를 응축해 액체 상태로 만드는 방법이고, 압착법은 물질을 눌러서 기름 같은 성분을 짜내는 방법으로 주로 식물유지의 채취에 사용되고 있는 방법이다.Reflux extraction is a method of boiling a liquid to make water vapor and condensing it into a liquid state. Compression method is a method of squeezing oil-like components by pressing the material, and is mainly used for harvesting plant oils.
이 이외에도 당업계에 알려진 천연물로부터 추출물을 수득하는 방법을 모두 본 발명에 적용할 수 있다. In addition to this, all of the methods for obtaining extracts from natural products known in the art can be applied to the present invention.
또한, 목적하는 추출물은 추가로 통상의 분획 공정을 수행할 수도 있으며, 통상의 정제 방법을 이용하여 정제될 수도 있다. 본 발명의 생강 비극성 추출물의 제조방법에는 제한이 없으며, 공지되어 있는 어떠한 방법도 이용될 수 있다.In addition, the desired extract may be further subjected to a conventional fractionation process or may be purified using a conventional purification method. There is no limitation on the production method of the ginger non-polar extract of the present invention, and any known method can be used.
따라서 본 발명에 있어서 생강 비극성 분획물 또는 수용성 분획물은 추출, 분획 또는 정제의 각 단계에서 얻어지는 모든 추출액, 분획 및 정제물, 그들의 희석액, 농축액 또는 건조물을 모두 포함하는 개념이다. Therefore, in the present invention, the ginger non-polar fraction or the water-soluble fraction is a concept including all the extract, fraction and purified product obtained in each step of extraction, fractionation or purification, a diluted solution thereof, a concentrate or a dried product.
이러한 생강 비극성 분획물 또는 수용성 분획물을 유효성분으로 포함하는 본 발명의 조성물은 약제학적 조성물일 수 있다. The composition of the present invention comprising such ginger non-polar fraction or water-soluble fraction as an active ingredient may be a pharmaceutical composition.
본 발명의 약제학적 조성물은 상기 유효성분 이외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다. The pharmaceutical composition of the present invention can be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, A lubricant or a flavoring agent can be used.
상기 약제학적 조성물은 투여를 위해서 상기 기재한 유효성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 약제학적 조성물로 바람직하게 제제화할 수 있다.The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.
상기 약제학적 조성물의 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 좌제, 액제, 시럽, 즙, 현탁제, 유제, 점적제 또는 주사 가능한 액제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다. 액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. 더 나아가 해당분야의 적절한 방법으로 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화 할 수 있다.The pharmaceutical composition may be in the form of granules, powders, tablets, coated tablets, capsules, suppositories, liquids, syrups, juices, suspensions, emulsions, drops or injectable solutions. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile solutions suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
본 발명의 일실시예에 있어서, 본 발명의 생강 비극성 분획물 또는 수용성 분획물은 조성물 총 중량에 대하여 0.1ug/ml 내지 500ug/ml의 농도로 포함될 수 있다.In one embodiment of the present invention, the ginger nonpolar fraction or water soluble fraction of the present invention may be contained at a concentration of 0.1 ug / ml to 500 ug / ml based on the total weight of the composition.
또한, 본 발명의 조성물은 또한 식품 조성물일 수 있는데, 이러한 식품 조성물은 유효성분인 생강 비극성 분획물 또는 수용성 분획물을 함유하는 것 외에 통상의 식품 조성물과 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. In addition, the composition of the present invention may also be a food composition. In addition to containing the ginger nonpolar fraction or water-soluble fraction as an active ingredient, such a food composition may contain various flavors or natural carbohydrates as an additional ingredient ≪ / RTI >
상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 향미제는 천연 향미제 (타우마틴), 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제 (사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. The above-described flavors can be advantageously used as natural flavorings (tau martin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.).
본 발명의 식품 조성물은 상기 약제학적 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 육류, 초코렛, 식품류, 과자류, 피자, 라면, 기타 면류, 껌류, 사탕류, 아이스크림류, 알코올 음료류, 비타민 복합제 및 건강보조식품류 등이 있다.The food composition of the present invention can be formulated in the same manner as the above pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolates, foods, confectionery, pizza, ram noodles, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, .
또한 상기 식품 조성물은 유효성분인 생강 비극성 분획물 또는 수용성 분획물 외에 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 식품 조성물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. In addition, the food composition may further contain flavorings such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate, etc.) Acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the food composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks.
본 발명의 유효성분인 생강 비극성 분획물 또는 수용성 분획물은 천연물질로서 독성 및 부작용은 거의 없으므로 배뇨장애의 예방 및 치료를 위한 목적으로 장기간 복용 시에도 안심하고 사용할 수 있다.Since the ginger nonpolar fraction or water soluble fraction as an active ingredient of the present invention is a natural substance with little toxicity and side effects, it can be safely used for long-term administration for the purpose of prevention and treatment of voiding dysfunction.
본 발명의 건강기능식품은 위장관 운동장애 예방 및 치료를 위한 목적으로 정제, 캅셀, 분말, 과립, 액상, 환 등의 형태로 제조 및 가공할 수 있다.The health functional food of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and circles for the purpose of preventing and treating gastrointestinal motility disorders.
본 발명에서 “건강기능식품”이라 함은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 말하며, 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.In the present invention, the term " health functional food " refers to foods manufactured and processed using raw materials or ingredients having useful functions in accordance with Law No. 6727 on Health Functional Foods. Or to obtain a beneficial effect in health use such as physiological action.
본 발명의 건강기능식품은 통상의 식품 첨가물을 포함할 수 있으며, 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전청에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.The health functional foods of the present invention may contain conventional food additives and, unless otherwise specified, whether or not they are suitable as food additives are classified according to the General Rules for Food Additives approved by the Food and Drug Administration, Standards and standards.
상기 “식품 첨가물 공전”에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼슘, 니코틴산, 계피산 등의 화학적 합성물; 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물; L-글루타민산나트륨제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류 등을 들 수 있다.Examples of the items listed in the above-mentioned "food additives" include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as persimmon extract, licorice extract, crystalline cellulose, high color pigment and guar gum; L-glutamic acid sodium preparations, noodle-added alkalis, preservative preparations, tar coloring preparations and the like.
예를 들어, 정제 형태의 건강기능식품은 본 발명의 유효성분인 생강 비극성 분획물 또는 수용성 분획물을 부형제, 결합제, 붕해제 및 다른 첨가제와 혼합한 혼합물을 통상의 방법으로 과립화한 다음, 활택제 등을 넣어 압축성형하거나, 상기 혼합물을 직접 압축 성형할 수 있다. 또한 상기 정제 형태의 건강기능식품은 필요에 따라 교미제 등을 함유할 수도 있다.For example, the health functional food in the form of tablets may be prepared by granulating a mixture of ginger nonpolar fraction or water-soluble fraction, which is an active ingredient of the present invention, with an excipient, a binder, a disintegrant and other additives in a usual manner, And the mixture can be directly compression-molded. In addition, the health functional food of the tablet form may contain a mating agent or the like if necessary.
캅셀 형태의 건강기능식품 중 경질 캅셀제는 통상의 경질 캅셀에 본 발명의 유효성분인 생강 비극성 분획물 또는 수용성 분획물을 부형제 등의 첨가제와 혼합한 혼합물을 충진하여 제조할 수 있으며, 연질 캅셀제는 생강 비극성 분획물 또는 수용성 분획물을 부형제 등의 첨가제와 혼합한 혼합물을 젤라틴과 같은 캅셀기제에 충진하여 제조할 수 있다. 상기 연질 캅셀제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다.The hard capsule of the capsule type health functional food can be prepared by filling a normal hard capsule with a mixture of ginger nonpolar fraction or water soluble fraction as an active ingredient of the present invention mixed with an additive such as an excipient and the soft capsule contains ginger nonpolar fraction Or a mixture in which a water-soluble fraction is mixed with an additive such as an excipient into a capsule base such as gelatin. The soft capsule may contain a plasticizer such as glycerin or sorbitol, a coloring agent, a preservative and the like, if necessary.
환 형태의 건강기능식품은 본 발명의 유효성분인 생강 비극성 분획물 또는 수용성 분획물과 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 제피제로 제피할 수 있으며, 또는 전분, 탈크와 같은 물질로 표면을 코팅할 수도 있다.The ring-shaped health functional food can be prepared by molding a mixture of ginger nonpolar fraction or water-soluble fraction, which is an effective ingredient of the present invention, with excipient, binder, disintegrant, etc., by a conventionally known method. It can be applied to other skin preparations, or the surface can be coated with materials such as starch, talc.
과립 형태의 건강기능식품은 본 발명의 유효성분인 생강 비극성 분획물 또는 수용성 분획물과 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다.The granular health functional food may be prepared by granulating a ginger nonpolar fraction or a water soluble fraction, which is an effective ingredient of the present invention, with a mixture of an excipient, a binder and a disintegrant in a conventional manner, , A mating agent, and the like.
상기 건강기능식품은 음료류, 육류, 초코렛, 식품류, 과자류, 피자, 라면, 기타 면류, 껌류, 사탕류, 아이스크림류, 알코올 음료류, 비타민 복합제 및 건강보조식품류 등일 수 있다.
The health functional food may be a beverage, a meat, a chocolate, a food, a confectionery, a pizza, a ramen, a noodle, a gum, a candy, an ice cream, an alcoholic beverage, a vitamin complex and a health supplement food.
이하, 본 발명을 실시예에 의해 상세히 설명하기로 한다. 그러나 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to examples. However, these examples are intended to further illustrate the present invention, and the scope of the present invention is not limited to these examples.
<< 실시예Example 1> 1>
생강 추출물의 제조Production of ginger extract
생강 300g을 플라스크에 넣고 메탄올(methanol) 2L를 첨가하여 실온에서 1 일씩 2 회 반복 추출을 수행하였다. 거름종이로 추출물을 거른 후, 회전감압농축하여 메탄올 추출물 21g(수율 7%)을 얻었다. 이후 상기 메탄올 추출물을 물에 현탁한 후, 노말헥산(n-Hexane), 디클로로메탄(dichloromethane, CH2Cl2), 에틸아세테이트(ethyl acetate, CH3COOCH2CH3), 물을 각각 순서대로 첨가하여 분획화하였고, 각각 수득한 분획을 회전감압농축하여 9.2g(노말헥산 분획물), 2.2g(디클로로메탄 분획물), 2.5g(에틸아세테이트 분획물), 6.9g(물 분획물)의 용매 분획추출물을 얻었다.상기 수득한 노말헥산 분획물과 에틸아세테이트 분획물은 디메틸설폭사이드(demethyl sulfoxide, DMSO)에 100mg/㎖ 농도로 녹인 다음, 실험동물의 적출장기 실험에 이용하는 장기수조(organ bath)에 넣었더니 배양액에 닿자마자 물에 녹지 않는 거품이 생겨서 실험을 진행할 수 없었다. 300 g of ginger was placed in a flask, 2 L of methanol was added, and repeated extraction was performed twice at room temperature for 1 day. The extract was filtered with a filter paper, and then concentrated under reduced pressure to obtain 21 g of a methanol extract (yield: 7%). Thereafter, the methanol extract was suspended in water, and then n-hexane, dichloromethane (CH 2 Cl 2 ), ethyl acetate (CH 3 COOCH 2 CH 3 ) and water were added sequentially , And the obtained fractions were concentrated under reduced pressure to obtain a solvent fraction extract of 9.2 g (fraction of normal hexane), 2.2 g (fraction of dichloromethane), and 2.5 g of fraction of ethyl acetate (fraction of ethyl acetate) and 6.9 g of fraction of water . The obtained n-hexane fraction and ethyl acetate fraction were dissolved in demethyl sulfoxide (DMSO) at a concentration of 100 mg / ml and then placed in an organ bath used for an experiment for the extraction of an experimental animal. As soon as the bubbles were not soluble in water, the experiment could not proceed.
이에 본 발명자들은 상기 메탄올 추출물을 디클로로메탄과 물로 순차적으로 다시 분획하였고, 여기에서 얻은 물 분획을 생강의 수용성 분획물(Ginger-H)이라고 칭하였고, 디클로로메탄 분획을 비극성 분획물(Ginger-C)로 칭하였으며, 이들로 하기 실험을 진행하였다.
Therefore, the present inventors divided the methanol extract into dichloromethane and water in order, and the water fraction was called a ginger-water soluble fraction (Ginger-H). The dichloromethane fraction was designated as a non-polar fraction (Ginger-C) And the following experiment was conducted.
<< 실시예Example 2> 2>
기니피그 guinea pig 위조직Stomach tissue 윤상근(circular muscle)의Of the circular muscle 자발적 수축에 대한 생강 수용성 Ginger water solubility for voluntary contraction 분획물의Fraction 효과 1 Effect 1
상기 실시예 1을 통해 제조한 생강 수용성 분획물(Ginger-H)이 위장관 운동을 조절하는 효과가 있는지를 알아보기 위하여 기니피그 위 날문방(gastric antrum)의 윤상근 조직(circular muscle)을 사용하였고, 상기 위 조직을 25㎖ 생리적 완충용액(physiologoical salt solution)이 들어있는 장기수조(organ bath)에서 등장성수축력 측정기(isometric force transducer)에 연결하였다. 또한, 실시예 1에서 제조한 생강 수용성 분획(Ginger-H)은 디메틸설폭사이드(dimethyl sulfoxide, DMSO)에 100mg/㎖로 녹였다. A circular muscle of the gastric antrum was used to determine whether the ginger-soluble fraction (Ginger-H) prepared in Example 1 had an effect of controlling gastrointestinal motility, The tissue was connected to an isometric force transducer in an organ bath containing a 25 ml physiologic salt solution. The ginger-soluble fraction (Ginger-H) prepared in Example 1 was dissolved in dimethyl sulfoxide (DMSO) at 100 mg / ml.
25㎖의 생리적 완충용액에 생강의 수용성 분획물을 최종농도가 200㎍/㎖, 400㎍/㎖, 800㎍/㎖, 2000㎍/㎖, 3200㎍/㎖이 되도록 첨가하였을 때, 각각의 농도에서 기니피그 위 조직의 자발적 수축의 변화를 관찰하였다. When water soluble fractions of ginger were added to 25 ml of physiological buffer solution to a final concentration of 200 μg / ml, 400 μg / ml, 800 μg / ml, 2000 μg / ml and 3200 μg / ml, Changes in spontaneous contraction of the stomach tissue were observed.
그 결과, 생강의 수용성 분획물의 농도에 비례하여 기니피그 위조직 윤상근의 자발적 수축이 증가하는 것으로 나타났다(도 2 참조).As a result, the voluntary contraction of the guinea pig gastric tissue was increased in proportion to the concentration of the water-soluble fraction of ginger (see FIG. 2).
따라서 이러한 결과를 통해 본 발명자들은 본 발명에서 제조한 생강의 수용성 분획물이 위조직의 자발적 수축을 증가시킨다는 것을 알 수 있었다.
Therefore, the inventors of the present invention have found that the water-soluble fraction of ginger prepared in the present invention increases spontaneous contraction of the stomach tissue.
<< 실시예Example 3> 3>
기니피그 guinea pig
위조직Stomach tissue
윤상근의Yoon Sang Keun
자발적 수축에 대한 수용성 Water solubility for voluntary
상기 실시예 1을 통해 제조한 생강 수용성 분획물(Ginger-H)이 위장관 운동을 조절하는 효과가 있는지를 알아보기 위하여 기니피그 위 날문방(gastric antrum)의 윤상근 조직(circular muscle)을 사용하였다. 상기 위 조직을 25㎖ 생리적 완충용액(physiologoical salt solution)이 들어있는 장기수조(organ bath)에서 장력전환기에 연결하였다. A circular muscle of the gastric antrum was used to examine whether the ginger-soluble fraction (Ginger-H) prepared in Example 1 had an effect of regulating gastrointestinal motility. The stomach tissue was connected to a tension transducer in an organ bath containing 25 ml of physiologic salt solution.
상기 실시예 1의 생강의 수용성 분획(Ginger-H)은 디메틸설폭사이드(dimethyl sulfoxide, DMSO)에 100mg/㎖로 녹였다. 25㎖의 생리적 완충용액에 생강의 수용성 분획물을 최종농도가 200㎍/㎖, 400㎍/㎖, 800㎍/㎖, 2000㎍/㎖, 3200㎍/㎖가 되도록 농도를 증가시켰을 때, 각각의 농도에서 기니피그 위조직 윤상근의 자발적 수축에 따른 장력의 변화를 측정하였다.The water-soluble fraction (Ginger-H) of ginger in Example 1 was dissolved in dimethyl sulfoxide (DMSO) at 100 mg / ml. When the concentration of water soluble fraction of ginger was increased to a final concentration of 200 μg / ml, 400 μg / ml, 800 μg / ml, 2000 μg / ml and 3200 μg / ml in 25 ml of physiological buffer solution, We measured the change of the tension due to voluntary contraction of the guinea pig struc - ture.
그 결과, 기니피그 위 조직 윤상근의 자발적 수축은 생강의 수용성 분획물 투여전의 수축정도를 100%라 하였을 때, 400㎍/㎖일 때 175± 25%인 것으로 나타났고, 2000㎍/㎖일 때는 272± 110%인 것으로 나타났으며, 3200㎍/㎖일 때 613± 188%로 증가됨을 알 수 있었다(도 3 참조).
As a result, the spontaneous contraction of the gastric glandular tissue of guinea pig was 175 ± 25% when the shrinkage of ginger before administration of the water soluble fraction was 100%, and when it was 400 μg / ㎖, it was 272 ± 110 %, And increased to 613 ± 188% at 3200 μg / ml (see FIG. 3).
<< 실시예Example 4> 4>
사람 Person 위조직Stomach tissue 윤상근을Yun Sang-geun 대상으로 아세틸콜린 및 생강 수용성 분획에 의한 수축반응 유발효과 비교 분석 A Comparative Study on the Effect of Acetylcholine and Ginger Water Soluble Fraction on Shrinkage Reaction
위 조직은 아세틸콜린에 의하여 수축반응을 나타낸다. 아세틸콜린 투여 후 나타나는 수축반응은 초기의 peak 수축, peak 수축 이후의 위상성 수축(phasic contraction) 및 장력성 수축(tonic contraction)으로 나눌 수 있다. 장력성 수축과 위상성 수축은 겹쳐서 나타나며, 위상성 수축의 기준선을 연결하게 되면 장력성 수축정도를 측정할 수 있다. 즉, 위상성 수축은 장력성 수축위에 중첩되어 유발되며 위상성 수축의 기준선을 연결하게 되면 장력성 수축정도를 측정할 수 있다(도 4 참조).Stomach tissue shows contraction reaction by acetylcholine. The shrinkage reaction after acetylcholine administration can be divided into initial peak shrinkage, phasic contraction after peak shrinkage and tonic contraction. Tension contraction and phase contraction are superimposed, and the tension shrinkage can be measured by connecting the baseline of phase contraction. That is, the phase contraction is caused by overlapping on the tension contraction, and the tension contraction degree can be measured by connecting the baseline of the phase contraction (see FIG. 4).
사람 위조직 윤상근에서의 생강 수용성 분획(Ginger-H)에 의한 수축반응 유발효과를 아세틸콜린 단독처리에 의한 수축반응과 비교하였다. 이를 위해 실험에 사용한 사람 위 조직은 위 날문방(gastric antrum)의 윤상근 조직(circular muscle)을 사용하였고, 상기 위 조직을 25㎖ 생리적 완충용액이 들어있는 organ bath에서 등장성수축 측정기에 연결하였다. 생강의 수용성 분획(Ginger-H)은 DMSO에 100mg/㎖로 녹였다. 대조군으로서 위 조직에 아세틸콜린 10μM을 투여하여 수축의 크기를 측정한 값을 사용하였다.The effect of ginger-soluble fraction (Ginger-H) on the contraction of the human stomach tissue was compared with that of acetylcholine alone. For this purpose, the gastric antrum of the human gastric tissue was used and the stomach tissue was connected to an isotonic contraction measuring instrument in an organ bath containing a 25 ml physiological buffer solution. The soluble fraction of ginger (Ginger-H) was dissolved in DMSO at 100 mg / ml. As a control group, a value obtained by measuring the size of contraction by administering 10 μM of acetylcholine to stomach tissue was used.
여기에서 발생한 peak 수축, 위상성 수축, 장력성 수축의 크기를 각각 100%로 간주하였다. 이후, 아세틸콜린 10μM과 생강의 수용성 분획물이 동시에 나타내는 수축변화를 측정하기 위해, 생강의 수용성 분획물과 아세틸콜린을 2분 간격을 두고 투여한 다음, 발생하는 수축의 크기를 측정하였다. 위 조직이 담겨있는 생리적 완충용액에서 생강의 수용성 분획물과 아세틸콜린의 최종농도는 각각 1600㎍/㎖과 10μM으로 하였다.The peak shrinkage, phase shrinkage, and tensile shrinkage were considered as 100%, respectively. Then, in order to measure the shrinkage change simultaneously exhibited by 10 μM of acetylcholine and the water-soluble fraction of ginger, the water-soluble fraction of ginger and acetylcholine were administered at intervals of 2 minutes, and then the size of shrinkage occurred was measured. The final concentration of aqueous fraction of ginger and acetylcholine in the physiological buffer solution containing the stomach tissues was 1600 μg / ml and 10 μM, respectively.
그 결과, 아세틸콜린 단독에 의해 유발된 peak 수축, 위상성 수축, 장력성 수축의 크기를 각각 100%라 하면, 생강 수용성 분획 및 아세틸콜린에 의해서는 peak 수축이 223± 34%, 장력성 수축이 97± 66%, 위상성 수축이 216± 28%로 변하는 것으로 확인되었다. 즉, 장력성 수축은 아세틸콜린 단독 또는 생강 수용성 분획 병용투여에 의하여 유의한 변화가 없었으나, 생강의 수용성 분획은 아세틸콜린 단독에 의해 유발된 peak 수축 및 위상성 수축의 크기를 각각 2배 정도 증가시키는 것으로 나타났다(도 5 참조).
As a result, when the peak shrinkage, the phase shrinkage and the tensile shrinkage induced by acetylcholine alone were 100%, the peak shrinkage was 223 ± 34% and the tensile shrinkage was caused by the ginger water soluble fraction and acetylcholine, 97 ± 66%, and phase contraction to 216 ± 28%. In other words, there was no significant change in the tensile contraction by the administration of acetylcholine alone or in combination with the ginger water soluble fraction, but the water soluble fraction of the ginger increased the peak shrinkage and phase contraction induced by acetylcholine alone by about 2 times (See FIG. 5).
<< 실시예Example 5> 5>
사람 Person 위조직의Above 자발적 수축에 대한 생강의 비극성 Non-polarity of ginger for voluntary contraction 분획물Fraction 효과 분석 Effect analysis
생강의 비극성 분획물(Ginger-C, 생강의 디클로로메탄 분획물)의 효과를 알아보기 위해 실험에 사용한 사람 위 조직은 위 날문방(gastric antrum)의 윤상근 조직(circular muscle)을 사용하였고, 상기 위 조직을 25㎖ 생리적 완충용액이 들어있는 organ bath에 장력전환기에 연결하고, 등장성수축(isometric contraction)의 장력변화를 측정하였다. 생강의 비극성 분획은 DMSO에 100mg/㎖로 녹였다. 25㎖의 영양액에 생강의 비극성 분획물을 최종농도가 200㎍/㎖, 400㎍/㎖, 800㎍/㎖가 되도록 투여하여?.In order to investigate the effect of the non-polar fraction (Ginger-C, ginger's dichloromethane fraction) of ginger, the human gastric tissue used in the experiment was a circular muscle of the gastric antrum, The organ bath containing 25 ml of physiological buffer solution was connected to a tension transducer and the change in tension of isometric contraction was measured. The non-polar fraction of ginger was dissolved in DMSO at 100 mg / ml. The nonpolar fraction of ginger was added to 25 ml of the nutrient solution to a final concentration of 200 μg / ml, 400 μg / ml and 800 μg / ml.
그 결과, 생강의 비극성 분획물 투여전의 장력을 대조군으로 하여 100%로 한다면, 생강 비극성 분획물 투여 후에는 장력이 각각 25± 15%, 2± 2%, 0%로 감소하였다(도 6 참조).
As a result, when the non-polar fraction of ginger was used as the control, the tension was reduced to 25 ± 15%, 2 ± 2%, and 0%, respectively, after administration of the ginger nonpolar fraction (see FIG.
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특허청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.The present invention has been described with reference to the preferred embodiments. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.
Claims (7)
상기 생강은 생강의 가지, 잎, 뿌리 및 생강 전체로 이루어진 군에서 선택되는 생강 부위를 사용한 것을 특징으로 하는 기능성 위장장애 및 위장관 운동장애의 예방 및 치료용 약학적 조성물.The method according to claim 1,
Wherein the ginger is a ginger portion selected from the group consisting of ginger branches, leaves, roots and whole ginger. The pharmaceutical composition for preventing and treating functional gastrointestinal disorder and gastrointestinal motility disorder according to claim 1,
상기 수용성 분획물은 물 분획물이며, 상기 비극성 분획물은 디클로로메탄 분획인 것을 특징으로 하는 기능성 위장장애 및 위장관 운동장애의 예방 및 치료용 약학적 조성물.The method according to claim 1,
Wherein the water-soluble fraction is a water fraction, and the non-polar fraction is a dichloromethane fraction, wherein the non-polar fraction is a fraction of dichloromethane.
상기 물 분획물은 생강의 메탄올 추출물에 물을 첨가하여 현탁한 후 물 분획물을 수득한 것이며, 상기 디클로로메탄 분획물은 생강의 메탄올 추출물에 디클로로메탄을 첨가하여 수득한 것을 특징으로 하는 기능성 위장장애 및 위장관 운동장애의 예방 및 치료용 약학적 조성물. The method of claim 3,
Wherein the water fraction is obtained by adding water to a methanol extract of ginger to obtain a water fraction, and the dichloromethane fraction is obtained by adding dichloromethane to methanol extract of ginger to obtain a functional gastrointestinal disorder and gastrointestinal tract A pharmaceutical composition for the prevention and treatment of disorders.
상기 위장관 운동장애는 위식도 역류성 질환(gastroesophageal reflux disease), 위 마비(gastroparesis), 기능성 소화불량(functional dyspepsia), 과민성 대장증후군(irritable bowel syndrome), 대장 무력증(colonic inertia), 구토(vomiting), 당뇨병성 위장관 운동장애(diabetic gastrointestinal motility disorder), 화학요법 또는 약물(예, 아편양 진통제)로 인한 위장 운동장애, 소화관 운동장애로 인한 장폐색, 수술 후 장폐색증(postoperative ileus)을 포함하는 수술 후 위장관 기능 장애, 파킨슨병과 같은 퇴행성 신경질환과 관련한 위장관 운동장애, 변비(constipation)등으로 이루어진 군으로부터 선택된 1종 이상인 것을 특징으로 하는 위장관 운동장애 예방 및 치료용 약학적 조성물.The method according to claim 1,
The gastrointestinal motility disorder may be selected from the group consisting of gastroesophageal reflux disease, gastroparesis, functional dyspepsia, irritable bowel syndrome, colonic inertia, vomiting, Including gastrointestinal motility disorder due to diabetic gastrointestinal motility disorder, chemotherapy or drug (eg, opioid analgesic), intestinal obstruction due to gastrointestinal motility disorder, postoperative ileus, postoperative gastrointestinal function including postoperative ileus Disorder, gastrointestinal motility disorder associated with degenerative neurological diseases such as Parkinson's disease, constipation, and the like.
상기 기능성 위장장애 및 위장관 운동장애는 위식도 역류성 질환(gastroesophageal reflux disease), 위 마비(gastroparesis), 기능성 소화불량(functional dyspepsia), 과민성 대장증후군(irritable bowel syndrome), 대장 무력증(colonic inertia), 구토(vomiting), 당뇨병성 위장관 운동장애(diabetic gastrointestinal motility disorder), 화학요법 또는 약물(예, 아편양 진통제)로 인한 위장 운동장애, 소화관 운동장애로 인한 장폐색, 수술 후 장폐색증(postoperative ileus)을 포함하는 수술 후 위장관 기능 장애, 파킨슨병과 같은 퇴행성 신경질환과 관련한 위장관 운동장애, 변비(constipation)등으로 이루어진 군으로부터 선택된 1종 이상인 것을 특징으로 하는 기능성 위장장애 및 위장관 운동장애의 예방 및 개선용 건강기능식품.The method of claim 6,
The functional gastrointestinal disorder and gastrointestinal motility disorder may be selected from the group consisting of gastroesophageal reflux disease, gastroparesis, functional dyspepsia, irritable bowel syndrome, colonic inertia, vomiting, including gastrointestinal motility disorders due to vomiting, diabetic gastrointestinal motility disorder, chemotherapy or drugs (eg, opioid analgesics), intestinal obstruction due to digestive tract movement disorders, postoperative ileus A gastrointestinal dysfunction after surgery, a gastrointestinal motility disorder associated with degenerative neurological diseases such as Parkinson's disease, constipation, and the like, and a health functional food for preventing and improving gastrointestinal motility disorder .
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130099628A KR101549746B1 (en) | 2013-08-22 | 2013-08-22 | Composition comprising solvent fractionated extracts of Zingiber officinale, which are useful for the prevention, improvement and treatment of functional gastrointestinal and motility disorders |
| PCT/KR2014/007610 WO2015026107A1 (en) | 2013-08-22 | 2014-08-18 | Pharmaceutical composition for preventing and treating functional gastrointestinal disorders and gastrointestinal motility disorders, containing solvent fraction of ginger as active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130099628A KR101549746B1 (en) | 2013-08-22 | 2013-08-22 | Composition comprising solvent fractionated extracts of Zingiber officinale, which are useful for the prevention, improvement and treatment of functional gastrointestinal and motility disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150022177A true KR20150022177A (en) | 2015-03-04 |
| KR101549746B1 KR101549746B1 (en) | 2015-09-04 |
Family
ID=52483839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130099628A KR101549746B1 (en) | 2013-08-22 | 2013-08-22 | Composition comprising solvent fractionated extracts of Zingiber officinale, which are useful for the prevention, improvement and treatment of functional gastrointestinal and motility disorders |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101549746B1 (en) |
| WO (1) | WO2015026107A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210041801A (en) | 2019-10-08 | 2021-04-16 | 김덕회 | Manufacturing method including mixed fruits and health functional food including mixed fruits manufactured thereof |
| WO2022055287A1 (en) * | 2020-09-10 | 2022-03-17 | 강윤식 | Supplementary bowel-cleansing beverage |
| WO2022055286A1 (en) * | 2020-09-10 | 2022-03-17 | 강윤식 | Bowel-cleansing composition |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021150638A1 (en) * | 2020-01-20 | 2021-07-29 | Advanced Health Solutions LLC | Compositions and methods for improving visibility of the gastrointestinal tract for endoscopy procedures |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100542587B1 (en) * | 2003-11-17 | 2006-01-11 | 이화여자대학교 산학협력단 | Composition containing an extract of Zingiber cassumunar or the compound isolated therefrom for preventing and treating cancer disease |
| KR100989093B1 (en) * | 2008-01-18 | 2010-10-25 | 한화제약주식회사 | Composition Comprising the Extracts of Branch of Lindera obtusiloba for Prevention and Treatment of Cardiovascular Diseases |
| MX2011007686A (en) * | 2009-01-20 | 2011-08-12 | Indena Spa | Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome. |
| ITMI20090049A1 (en) * | 2009-01-20 | 2010-07-21 | Indena Spa | COMPOSITIONS BASED ON LIPOFILE EXTRACTS OF ZINGIBER OFFICINALE AND ECHINACEA ANGUSTIFOLIA FOR THE PREVENTION AND TREATMENT OF GASTRO-ESOPHAGEAL REFLOW AND CHEMOTHERAPY-INDUCED EMESIS |
| US8435575B2 (en) * | 2010-05-13 | 2013-05-07 | Aphios Corporation | Use of gingerols for cancer patients suffering from nausea and emesis induced by chemotherapy |
| KR101384633B1 (en) * | 2010-08-20 | 2014-04-11 | 최원형 | A composition for treating or preventing toxoplasmosis comprising Zingiber officinale extract and fractions thereof |
-
2013
- 2013-08-22 KR KR1020130099628A patent/KR101549746B1/en active IP Right Grant
-
2014
- 2014-08-18 WO PCT/KR2014/007610 patent/WO2015026107A1/en active Application Filing
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210041801A (en) | 2019-10-08 | 2021-04-16 | 김덕회 | Manufacturing method including mixed fruits and health functional food including mixed fruits manufactured thereof |
| WO2022055287A1 (en) * | 2020-09-10 | 2022-03-17 | 강윤식 | Supplementary bowel-cleansing beverage |
| WO2022055286A1 (en) * | 2020-09-10 | 2022-03-17 | 강윤식 | Bowel-cleansing composition |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101549746B1 (en) | 2015-09-04 |
| WO2015026107A1 (en) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6345243B2 (en) | Enbu fermented food or beverage composition | |
| KR101874462B1 (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Schisandra chinensis leaf extract as effective component | |
| KR101549746B1 (en) | Composition comprising solvent fractionated extracts of Zingiber officinale, which are useful for the prevention, improvement and treatment of functional gastrointestinal and motility disorders | |
| KR102227186B1 (en) | Composition comprising the extract of Belamcanda chinensis for preventing or treating neuro degenerative disease | |
| KR101565964B1 (en) | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia | |
| KR101292931B1 (en) | Composition Comprising Hedyotis diffusa extract for prevention or treatment of nonalcoholic fatty liver disease | |
| KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
| KR20160100279A (en) | Anti-cancer composition containing erythronium japonicum extract | |
| US20070053929A1 (en) | Marine algae extract and lipase inhibitor containing the same | |
| KR101808944B1 (en) | Composition for preventing and treating dysmenorrhea and premature labor comprising non-polar solvent subfraction from Zingiber officinale extract | |
| KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
| US20090318552A1 (en) | Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizo dor treating or preventing diabetes mellitus and the use thereof | |
| KR101248378B1 (en) | Pharmaceutical composition for arthritis treatment and prevention | |
| KR101994483B1 (en) | Pharmaceutical composition comprising the sprout extracts of zingiber officinale as an effective component for prevention or treatment of diabetes and health functional food comprising the same | |
| KR20110051545A (en) | Composition for preventing or treating gout comprising mulberry fermentation extract | |
| KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
| KR101221623B1 (en) | Food Composition for Stress Relaxation, Fatigue Recovery or Athletic Performance Enhancement Comprising Extract of root of vitis | |
| KR101780718B1 (en) | Pharmaceutical composition for preventing or treating diabetes mellitus comprising seed extract of platycodon | |
| KR101712889B1 (en) | Pharmaceutical composition comprising Zingiber mioga extracts or its fractions for prevention and treatment of neurodegenerative disorders as an active ingredient | |
| KR20150072659A (en) | Hepatoprotective composition containing smilax china extract | |
| KR20230139934A (en) | Composition for preventing or treating functional gastrointestinal disorders and gastrointestinal motility disorders comprising oleoresin ginger fraction as an active ingredient | |
| KR102275824B1 (en) | The anti-diabetes composition containing extract mixture and manufaturing method thereof | |
| KR20190066460A (en) | Pharmaceutical composition comprising the seed extracts of rambutan as an effective component for prevention or treatment of diabetes and health functional food comprising the same | |
| KR102183915B1 (en) | Composition containing complex extracts for improving blood circulation | |
| KR20240055932A (en) | Composition for preventing or treating functional gastrointestinal disorders and gastrointestinal motility disorders comprising shogaol from oleoresin ginger as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| FPAY | Annual fee payment |
Payment date: 20180801 Year of fee payment: 4 |
|
| R401 | Registration of restoration | ||
| R401 | Registration of restoration |